OPT-821

BIOLOGICAL2 trials

Sponsors

MabVax Therapeutics, Inc., Memorial Sloan Kettering Cancer Center

Conditions

NeuroblastomaSarcoma

Phase 2

Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

CompletedNCT01141491

MabVax Therapeutics, Inc.Sarcoma

Start: 2010-06-30End: 2017-03-10Updated: 2017-04-12

A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

RecruitingNCT04936529

Memorial Sloan Kettering Cancer CenterNeuroblastoma

Start: 2021-08-02End: 2027-06-15Target: 286Updated: 2026-08-11

Related Papers

A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery

European Journal of Cancer2022-10-0718 citations

Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial.

Journal of Clinical Oncology2014-05-2022 citations